



Certificate of Mailing (37 C.F.R. §1.8):

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:  
Mail Stop: DD, Commissioner for Patents,  
PO Box 1450, Alexandria, VA 22313-1450  
on this 20th day of August 2003.

s/

*Bonnie Acosta*  
Bonnie Acosta

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
David MATTHEWS et al.

Serial No.: 10/616,003

Filed: July 8, 2003

For: PIN1 Peptidyl-Prolyl Isomerase  
Polypeptides, Their Crystal Structures, And  
Use Thereof For Drug Design

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)**

Mail Stop: DD  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the art documents listed on the attached Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified at 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached Form PTO-1449 and returning a copy of the initialed form to Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified at 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Karl Neidert", is written over a horizontal line.


Karl Neidert  
Attorney For Applicants  
Registration No. 39,313

Date: August 20, 2003

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Legal Division, Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-8060  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
		US 5,952,467	09-14-1999	Tony HUNTER et al.	
		US 5,972,697	10-26-1999	Tony HUNTER et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		01/0016346 A1	08-23-2001	Joseph P. NOEL et al.		
		WO99/12962	03-18-1999	Beth Israel Deaconess		
		WO99/63931	12-16-1999	Salk Inst. For Bio. Studies		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICATION**

(Us as many sheets as n c ssary)

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ABRAHAMS et al., "Methods Used in the Structure Determination of Bovine Mitochondrial F1 ATPase", Acta Cryst., 1996, 30-42, D52.	
		ALTSCHUL et al., "Basic Local Alignment Search Tool," J. Mol. Biol., 1990, 403-10, 215.	
		ALTSCHUL et al., "Gapped BLAST and PSI-BLAST: A new Generation of Protein Database Search Programs," Nucleic Acids Res., 1997, 3389-3402, 25(17).	
		AMANN et al., "Tightly Regulated tac Promoter Vectors Useful for the Expression of Unfused and Fused Proteins in Escherichia coli." Gene, 1988, 301-315, 69.	
		APPELT, K., "Crystal Structures of HIV-1 Protease-inhibitor Complexes," Perspectives in Drug Discovery and Design, 1993, 23-48, 1.	
		AUSUBEL et al., eds. "Current Protocols in Molecular Biology," 1994, Green Publishers Inc. and Wiley and Sons, NY.	
		BALBES et al., "A Perspective of Modern Methods of Computer-Aided Drug Design," Reviews in Computational Chemistry, 1994, 337-380, 5, VCH, NY.	
		BALDARI et al., "A Novel Leader Peptide which Allows Efficient Secretion of a Fragment of Human Interleukin 1B in Saccharomyces Cerevisiae," EMBO J., 1987, 229-234, 6.	
		BARTLETT et al., "CAVEAT: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules," 1989, 182-196, 78, Special Pub., Royal Chem. Soc.	
		BOHM, "The Computer Program LUDI: A New Method for the Design of Enzyme Inhibitors," J. Comp. Aid. Molec. Design, 1992, 61-78, 6.	
		BOUZIDA et al., "Computer Simulations of Ligan-Protein Binding with Ensembles of Protein Conformations: A Monte Carlo Study of HIV-1 Protease Binding Energy Landscapes," Internat. J of Quantum Chem. 1999, 73-84, 72.	
		BOUZIDA et al., "Thermodynamics and Kinetics of Ligand-protein Binding Studied with the Weighted Histogram Analysis Method and Simulated Annealing," Pacific Symp. on Biocomputing '99, 1999, 426-437.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.


Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)



		BOWIE et al., "Diciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science, 1990, 1306-1310, 247.	
		BRUNGER, A., "X-PLOR: A System for X-ray Crystallography and NMR," 1992, Yale University Press, New Haven, Conn.	
		BUGG et al., "Drugs by Design," Scientific American Dec., 1993, 92-98.	
		COHEN et al., "Molecular Modeling Software and Methods for Medicinal Chemistry," J. Med. Chem., 883-894, 33.	
		CREIGHTON, "Proteins-Structure and Molecular Properties," 2nd ed., 1993, W.H. Freeman and Company, NY	
		CRENSHAW et al., "The Mitotic Peptidyl-prolyl Isomerase, Pin 1, Interacts with Cd25 and Plx1," EMBO J., 1998, 1315-1327, 17.	
		CUNNINGHAM et al., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," Science, 1989, 1081-1085, 244.	
		DAVIS et al., "Monoclonal Antibodies to Mitotic Cells," Proc. Natl. Acad. Sci. USA, 1983, 2926-2930, 80.	
		DE LA FORTELLE et al., "[27] Maximum-likelihood Heavy-Atom Parameter Refinement for Multiple Isomorphous Replacement and Multiwavelength Anomalous Diffraction Methods," Meth. Enzymol. 1997 472-494 276	
		DUNBRACK et al., "Meeting Review: the Second Meeting on the critical Assessment of Techniques for Protein Structure Prediction (CASP2) Asilomar, Calif.,," Folding & Design, 1997, 27-42 2 vv	
		DUVEREUX et al., "A Comprehensive Set of Sequence Analysis Programs for the VAX," Nucleic Acids Res., 1984, 387, 12(1).	
		EISEN et al., "HOOK: A Program for Finding Novel Molecular Architectures that Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site," Proteins: Struct. Funct. Genet. 1994 199-221 19	
		ELDRIDGE et al., "Empirical Scoring Functions: 1. The Development.....," J. Comput. Aided Mol. Des., 1997, 425-445, 11.	
		ERICKSON, J., "Design and Sgstructure of Symmetry-based Inhibitors of HIV-1 Protease," Perspectives in Drug Discovery and Design, 1993, 109-128, 1.	
		FRESHNEY, R., "Culture of Animal Cells: A Manual of Basic Technique," 4th ed., 2000, Wiley & Sons.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. 1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.


Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICATION**

(Use as many sheets as necessary)



	GEHLHAAR et al., "Fully Automated and Rapid Flexible Docking of Inhibitors Covalently Bound to Serine Proteases," Proceedings of the Seventh Ann. Conf. on Evolutionary Programming, 1998, The MIT Press, Cambridge, MA	
	GEHLHAAR et al., "Molecular Recognition of the Inhibitor AG-1343 by HIV-1 Protease: Conformationally Flexible Docking by Evolutionary Programming," Chemistry & Biol., 1995, 317-324, 2	
	GILLET et al., "SPROUT: A Program for Structural Generation," J. Comput. Aided Mol. Design, 1993, 127-153, 7.	
	GLOVER et al., "DNA Cloning: A Practical Approach," Volumes I and II, 2nd, 1995, IRL Press, Oxford.	
	GOODFORD, "A Computational Procedure for Determining Energetically Favorable Sites on Biologically Important Macromolecules," J. Med. Chem., 1985, 849-857, 28.	
	GOODSELL et al., "Automated Docking of Substrates.....," Proteins: Struct. Funct. and Genet., 1990, 195-202, 8.	
	GOTTESMAN, S., [11] Minimizing Proteolysis in Escherichia coli: Genetic Solutions," Gene Expression Technology: Methods in Enzymology, 1990, 119-128, 185.	
	GRIBSKOV, ET AL., "Sequence Analysis in Molecular Biology," 1987, Academic Press, NY.	
	GRIFFIN et al., eds., "Computer Analysis of Sequence Data, Part 1," 1994, Humana Press, NJ.	
	GUIDA, W., "Software for Structure-based Drug Design," Curr. Opin. Struct. Biol., 1994, 777-781, 4.	
	HANES et al., "Sequence and Mutational Analysis of ESSI.....," Yeast, 1989, 55-72, 5.	
	HENNIG et al., "Selective Inactivation of Parvulin-Like peptidyl-Prolyl cis/trans Isomerases by Juglone," Biochemistry, 1998, 5953-5960, 37.	
	INNIS et al., eds. "PCR Protocols: A Guide to Methods and Applications," 1990, Academic Press, San Diego.	
	JOHNSON, B., ed., "Posttranslational Covalent Modification of Proteins," 1983, Academic Press, NY.	
	JONES et al., "Development and Validation of a Genetic Algorithm for Flexible Docking," J. Mol. Biol., 1997, 727-748, 267.	

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

	JONES et al., "Improved Methods for Building Protein Models in Electron Density maps and the Location of Errors in these Models," Acta Crystallogr., 1991, 110-119, A47.
	KAUFMAN et al., "Translational Efficiency of Polycistronic mRNAs and their Utilization to Express Heterologous Genes in Mammalian Cells," EMBO J., 1987, 187-195, 6.v
	KISSINGER et al., "Rapid Automated Molecular Replacement by Evolutionary Search," Acta Cryst., 1999, 484-491, D55.
	KOFRON et al., "Determination of Kinetic Constants for Peptidyl Prolyl Cis-Trans isomerases by an Improved Spectrophotometric Assay," Biochemistry, 1991, 6217-6134, 30.
	KONNERT et al., "A Restrained-Parameter Terhmal-Factor Refinement Procedure," Acta Cryst., 1980, 344-350, A36.
	KUNTZ et al., "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol., 1982, 269-288, 161.
	KUANG et al., "Mitosis-specific Momoclonal Antibody MPM-2 Inhibits Xenopus oocyte Maturation and Depletes Maturation-promoting Activity," Proc. Natl. Acad. Sci. USA 1989, 4982-4986, 86.
	KURJAN et al., "Structure of a Yeast Pheromone Gene ...," Cell, 1982, 933-943, 30.
	LAM et al., "Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors," Science, 1994, 380-384, 263.
	LAMZIN et al., "Automated Refinement of Protein Models," Acta Cryst., 1993, 129-147, D49.v
	LATTMAN, "Use of the Rotation and Translation Functions," Methods in Enzymology, 1985, 55-77, 115
	LAURI et al., "CAVEAT: A Program to Facilitate.....," 1994, 51-66, 8, University of California, Berkeley, CA.
	LU et al., "Functin of WW Domains as Phosphoserine- or.....," Science, 1999, 1325-1328, 283.
	LU et al., "A Human Peptidyl-prolyl Isomerase Essential for Regulation of Mitosis," Nature, 1996, 544-547, 380.
	LU et al., "Evidence for a NIMA-Like Mitotic pathway in Vertebrate Cells," Cell, 1995, 413-424, 81.

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. 1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

	LU et al., "The Prolyl isomerase Pin1 Restores the Function of Alzheimer-associated....," Nature, 1999, 784-788, 399.	
	LUCKLOW et al., "High Level Expression of Nonfused Foreign Genes with Autographa californica Nuclear Polyhedrosis Virus Expression Vectors," Virology, 1989, 31-39, 170.	
	MALESZKA et al., "The <i>dodo</i> gene family encodes.....," Gene, 1997, 89-93, 203.	
	MALESZKA et al., "The Drosophila Melanogaster Dodo (dod) Gene.....," Proc. Natl. Acad. Sci. USA, 1996, 447-451, 93.	
	MARTIN, "3D Database Searching in Drug Design," J. Med. Chem., 1992, 2145-2154, 35.	
	MENG et al., "Automated Docking with Grid-Based Energy Evaluation," J. Comp. Chem, 1992, 505-524, 13.	
	MIRANKER et al., "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method," Proteins Structure Func. & Genet., "Functionality Maps of Binding Sites.....," 1991, 29-34 11	
	MULLIS et al., "Specific Enzymatic Amplification of DNA," In Vitro: The Polymerase Chain Reaction," CSH Symp. Quantum Biol., 1986, 263-273, 51.	
	MYERS et al., "Optimal Alignments in Linear Space," CABIOS, 1989, 11-17, 4.	
	NAVAZA, J., "AMoRe: an Automated Package for Molecular Replacement," Acta Crystallographica ASO, 1994, 157-163.	
	NAVIA et al., "Use of Structural Information in Drug Design," Curr. Opin. Struct. Biol., 1992, 202-210, 2.	
	NEEDLEMAN, et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," J. Mol. Biol., 1970, 444-453, 48.v	
	NURSE, P., "Universal Control mechanism Regulating Onset of M-Phase, Nature, 1990, 503-508, 344.	
	OTWINOWSKI et al., [20] Processing of X-Ray Diffraction Data Collected in Oscillation Mode," Methods in Enzymology, 1997, 307-326, 276.	
	PERBAL, B., "A Practical Guide to Molecular Cloning," 2nd ed., 1998, Wiley & Sons.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. 1Applicant's unique citation designation number (optional). 2See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICATION**  
(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

	PERRAKIS et al., "Automated Protein Model building Combined with Iterative Structure Refinement," Nature Struct. Biol., 1999, 458-463, 6.	
	RANGANATHAN et al., "Structural & Functional Analysis of the Mitotic Rotamase Pin 1 Suggests Substrate Recognition....," Cell, 1997, 875-886, 89.	
	RATTAN et al., "Protein Synthesis, Posttranslational Modifications, and Aging....," Ann NY Acad. Sci., 1992, 48-62, 663.	
	RITCHIE et al., "Protein Docking Using Spherical Polar Fourier Correlations," Proteins: Struct. Funct. & Genet, 2000, 178-194, 39.	
	SAIKI et al., "Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase," Science, 1988, 487-491, 239.	
	SAMBROOK et al., "Molecular Cloning: A Laboratory Manual," 3rd ed., 2001, Cold Spring Harbor Press, Cold Spring Harbor, NY.	
	SCHMID, F., Prolyl Isomerases Join the Fold, Current Biology, 1995, 993-994, 5.	
	SCHULTZ et al., "Expression and Secretion in Yeast of a 400-k Da Envelope Glycoprotein Derived from Epstein-Barr Virus," Gene, 1987, 113-123, 54.	
	SEED, B., "An LFA-3 cDNA Encodes a Phospholipid-linked Membrane Protein Homologous to its Receptor CD2," Nature, 1987, 840, 329.	
	SEIFTER et al., "Analysis for Protein Modifications and Nonprotein Cofactors," Methods in Enzymology, 1990, 626-646, 182.	
	SHEN et al., "The Essential Mitotic Peptidyl-prolyl Isomerase Pin1 binds and regulates Mitosis-specific Phosphoproteins," Genes & Development, 1998, 706, 12.	
	SMITH et al., "Human Interleukin 4, The Solution Structure of a Four-helix Bundle Protein," J. Mol. Biol., 1992, 899-904, 224.	
	SMITH et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Mol. Cell Biol., 1983, 2156-2165, 3.	
	SMITH et al., "Single Step Purification of Polypeptides Expressed in Escherichia coli as Fusions with Glutathione S-transferase," Gene, 1988, 31-40, 67.	
	SMITH, D., "Biocomputing: Informatics and Genome Projects," 1993, Academic Press, NY.	

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICATION

(Us as many she ts as n c ssary)

**Complete if Known**

Application Number	10/616,003
Filing Date	July 8, 2003
First Named Inventor	David MATTHEWS et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	PC19084A/AG0116-US

	STUCKENBERG et al., "Systematic Identification of Mitotic Phosphoproteins," Curr. Biol., 1997, 338-348, 7.	
	STUDIER et al., "[6] Use of T7 RNA Polymerase to Direct Expression of Cloned Genes," Gene Expression Technology: Methods in Enzymology, 1990, 60-89, 185.	
	WADA et al., "Godon Usage Tabulated from the GenBank Genetic Sequence Data," Nucleic Acids Res., 1992, 2111-2118, 20.	
	WEST et al., "Targeting HIV-1 Protease: a Test of Drug-design Methodologies," TIPS, 1995, 67-74, 16.	
	WESTENDORF et al., "Cloning of cDNAs for M-phase Phosphoproteins Recognized by the MPM2 Monoclonal Antibody and ....," Proc. Natl. Acad. Sci. USA, 1994, 714-718, 91.	
	WLODAWER et al., "Structure-Based Inhibitors of HIV-1 Protease," Ann. Rev. Biochem, 1993, 543-585, 62.	
	YAFFE et al., "Sequence-Specific and Phosphorylation-Dependent Proline Isomerization: A Potential Mitotic Regulatory Mechanism," Science, 1997, 1957-1960, 278.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901-04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Mail Stop: DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.